Shanghai Pharmaceuticals Holding's (SHA:601607, HKG:2607) drug supplementary application for salbutamol sulfate injection has passed the Chinese drug administration's consistency evaluation, according to a Shanghai bourse filing on Tuesday.
The drug was tested for its consistency in quality and efficacy.
The pharmaceutical company's subsidiary, Shanghai Hefeng Pharmaceutical, developed the drug to treat respiratory diseases, such as bronchial asthma and asthmatic bronchitis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.